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Abstract
Objective To identify associated (non-)motor profiles of Parkinson’s disease (PD) patients with hyperhidrosis as a dominant 
problem.
Methods This is a cross-sectional, exploratory, analysis of participants enrolled in the Non-motor Longitudinal International 
Study (NILS; UKCRN No: 10084) at the Parkinson’s Centre at King’s College Hospital (London, UK). Hyperhidrosis scores 
(yes/no) on question 28 of the Non-Motor Symptom Questionnaire were used to classify patients with normal sweat func-
tion (n = 172) and excessive sweating (n = 56) (Analysis 1; n = 228). NMS scale (NMSS) question 30 scores were used to 
stratify participants based on hyperhidrosis severity (Analysis 2; n = 352) using an arbitrary severity grading: absent score 0 
(n = 267), mild 1–4 (n = 49), moderate 5–8 (n = 17), and severe 9–12 (n = 19). NMS burden, as well as PD sleep scale (PDSS) 
scores were then analysed along with other correlates.
Results No differences were observed in baseline demographics between groups in either analysis. Patients with hyperhi-
drosis exhibited significantly higher total NMSS burden compared to those without (p < 0.001). Secondary analyses revealed 
higher dyskinesia scores, worse quality of life and PDSS scores, and higher anxiety and depression levels in hyperhidrosis 
patients (p < 0.001). Tertiary analyses revealed higher NMSS item scores for fatigue, sleep initiation, restless legs, urinary 
urgency, and unexplained pain (p < 0.001).
Conclusions Chronic hyperhidrosis appears to be associated with a dysautonomia dominant subtype in PD patients, which 
is also associated with sleep disorders and a higher rate of dyskinesia (fluctuation-related hyperhidrosis). These data should 
prompt the concept of hyperhidrosis being used as a simple clinical screening tool to identify PD patients with autonomic 
symptoms.
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Introduction
Hyperhidrosis is one of the least studied non-motor symp-
toms (NMS) in Parkinson’s disease (PD). Sweating disor-
ders in PD include mainly hyperhidrosis, but also hypo-
hydrosis, and the prevalence is reported by some at 64% 
of PD patients, compared to 12.5% of healthy controls 
[1]. Phenomenologically, hyperhidrosis in PD could be 
chronic or paroxysmal, on the one hand, and non-fluctu-
ating or related to non-motor fluctuations, on the other 
[2]. The phenomenon of hyperhidrosis may also overlap 
with an increase of sebum excretion rate known as sebor-
rhoea which is also frequent in PD patients [3]. The patho-
physiology remains unclear but dysautonomia has been 
suggested as a possible correlate, while sweating occurs 
both during levodopa-induced motor fluctuations [4] and 
dyskinesia [5]. The pattern of dyshidrosis in PD appears 
to differ from the general population and axial hyperhi-
drosis in PD is associated with decreased activation of 
sweat glands in the palms of the hands suggesting that 
axial hyperhidrosis could be a compensatory phenomenon 
for reduced sympathetic function in the extremities [5].
Recently, Sauerbier et al. and Marras and Chaudhuri 
[6, 7] proposed several non-motor subtypes in PD, ana-
logues to the better-known motor subtypes. One of these 
phenotypes is an autonomic phenotype, with adrenergic/
cholinergic features (such as orthostatic hypotension) and 
gastro-intestinal symptoms overlapping with sleep dys-
function and levodopa-induced dyskinesias [6–8]. Here, 
we investigate, using validated tools (Non-Motor Ques-
tionnaire and Scale), whether in PD patients with self-
declared hyperhidrosis specific patterns of the autonomic 
subtype of PD exist.
Methods
This is a post hoc, exploratory study using the Non-motor 
International Longitudinal Study’s (NILS) international 
database. We used data from patients clinically diagnosed 
with idiopathic PD and whose data were entered between 
November 2011 and September 2018. We only included 
the baseline assessments (of five yearly longitudinal 
assessments) of patients seen at King’s College Hospital 
London (NHS Foundation Trust). The NILS Study is the 
world’s first non-motor focussed comprehensive longitudi-
nal cohort study addressing non-motor profiling of PD and 
the natural history of non-motor symptoms together with 
treatment response and clinico-pathological correlations. 
The study is adopted as a national study by the National 
Institute of Health Research in the UK (UKCRN No: 
10084) and involves 14 centres across Europe, but for the 
current study only patients who had a baseline assessment 
at King’s College Hospital were included. The study was 
authorised by local ethics committees (NRES SouthEast 
London REC3, 10084, 10/H0808/141). All patients gave 
written consent prior to study procedures in accordance 
with the Declaration of Helsinki. Exclusion criteria were 
(1) diagnosis of Parkinsonism different to idiopathic PD; 
(2) dementia (as per internationally accepted criteria); and 
(3) inability for giving consent to participate in the study.
Data extracted from the NILS database concerned 
sex, disease onset and duration (in years), and Levodopa 
equivalent dose (LEDD). Patient-reported outcomes 
were: Hospital Anxiety and Depression Scale (HADS; a 
14-item, patient-completed scale with subscales for anxi-
ety and depression) [10]; PDQ-8 (a specific instrument for 
assessment of health-related quality of life in PD) [11]; 
PD Sleep Scale-version 1 (PDSS), a 15-item, patient-
completed clinical tool used to assess the frequency of 
sleep disturbances during the past week in PD patients) 
[12], and Epworth Sleepiness Scale (ESS) scores (6-item 
tool looking at daytime sleepiness) [13]. Clinician-based 
evaluations were: Hoehn and Yahr (HY) staging [9] and 
Non-Motor Symptoms Scale (NMSS). The NMSS consid-
ers the frequency and severity of the non-motor symptoms 
of PD grouped into nine domains: cardiovascular, sleep/
fatigue, mood/apathy, perceptual problems/hallucinations, 
attention/memory, gastrointestinal tract, urinary function, 
sexual function, and miscellaneous [14, 15].
Hyperhidrosis scores on question 28 of the validated 
Non-Motor Symptom Questionnaire (NMSQ; when avail-
able) were used to classify patients with normal sweat 
function (n = 172) and hyperhidrosis (n = 56) (analysis 
1). In addition, we used the NMSS question 30 scores 
to stratify participants based on hyperhidrosis severity 
(analysis 2): absent score 0 (n = 267), mild scores 1–4 
(n = 49), moderate scores 5–8 (n = 17), and severe scores 
9–12 (n = 19). Subsequently, we assessed differences in 
NMS burden measured on the NMSS. Secondary and ter-
tiary outcomes included differences in specific non-motor 
(HADS, PDSS, ESS) and motor scores. As this was an 
exploratory analysis, we did not perform cluster analysis. 
Group differences were tested with Mann–Whitney U test 
or Kruskal–Wallis test, where appropriate. A Bonferroni 
correction was used to correct for multiple testing for the 
secondary (p = 0.05/8) and tertiary (p = 0.05/30) outcomes. 
To test for gender differences, Pearson Chi-square analysis 
was used. For correlations, Spearman’s analysis was used. 
All data were analysed using SPSS Version 24 (IBM SPSS 
Statistics for Windows, Version 24.0. Armonk, NY: IBM 
Corp.).
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Results
No differences were observed in age, gender, disease 
duration, and Levodopa Equivalent Dose (LED) between 
patients with and without hyperhidrosis (analysis 1). There 
were also no baseline differences in the NMSS defined 
groups (analysis 2), except a trend for LED (p = 0.017; 
Table 1). 160 of the 172 (93%) patients who indicated 
no sweating on the NMSQ had no hyperhidrosis on the 
NMSS scale (absent score) confirming the high concord-
ance between the NMSQ and NMSS.
In both analyses, patients with hyperhidrosis exhibited 
significantly higher NMSS total scores (analysis 1: 73.4 
vs 41.6; p < 0.001 and analysis 2: 41.9 for absent, 58.2 for 
mild, 77.8 for moderate, and 93.7 for severe; p < 0.001) 
(Fig. 1; Tables 1 and 2). Secondary analyses revealed, after 
correction for multiple testing, significantly higher Scales 
for Outcomes in PD (SCOPA) dyskinesia scores in hyper-
hidrosis patients (p < 0.001 for analysis 1 and p = 0.001 for 
analysis 2), worse quality of life scores (PDQ-8; p < 0.001 
both analyses), worse PDSS (p = 0.006 for analysis 1 and 
p < 0.001 analysis 2) and higher anxiety levels (p < 0.001 
for analysis 1 and p = 0.003 for analysis 2) and depression 
levels (p < 0.001 for analysis 1) on the Hospital Anxiety 
and Depression Scale (Tables 1 and 2). In addition, we 
correlated hyperhidrosis severity (defined by NMSS item 
30) with SCOPA dyskinesia scores, and also with SCOPA 
fluctuation presence and severity subitem scores. The 
analysis showed a significant positive correlation between 
hyperhidrosis severity and dyskinesia (for both SCOPA 
dyskinesia total scores, and subitems 20 and 21 for fluctua-
tion presence and severity; rho ≥ 0.162; p ≤ 0.002). 
Tertiary analyses, corrected for multiple testing, 
revealed higher NMSS scores for restless legs, urinary 
urgency and pain (analysis 1; p < 0.001; Table  1) and 
for fatigue, sleep initiation, and restless legs (analy-
sis 2; p < 0.001), with nearly significant trends for uri-
nary frequency, pain and anosmia (analysis 2; p = 0.004; 
Table 2). Moreover, there were significant positive corre-
lations between hyperhidrosis severity and fatigue, sleep 
initiation, restless legs, hyposmia, and weight change 
(rho ≥ 0.177; p < 0.001), with statistical trends for daytime 
sleepiness, depression, and urinary urgency (rho ≥ 0.158; 
p = 0.003).
Discussion
In this exploratory study, we observed a significantly 
higher NMS burden in PD patients with hyperhidrosis, 
especially among those with the most severe hyperhidrosis. 
Table 1  Demographics and (non-)motor profiles (non-motor symp-
tom questionnaire based) associated with hyperhidrosis in Parkinson’s 
disease
Statistical differences tested using Mann–Whitney U test
M male, F female, LED Levodopa equivalent dose, PDSS Parkinson’s 
disease sleep scale, ESS Epworth sleepiness scale, HADS hospital 
anxiety and depression scale, PDQ-8 8-item Parkinson’s disease qual-
ity of life scale, SCOPA Scales for outcomes in Parkinson’s disease
Analysis 1 (NMSQ item 28)
Hyperhidrosis No (n = 172) Yes (n = 56) P
Demographics
 Age (years) 64.7 ± 11.4 62.6 ± 10.8 0.20
 Gender (M/F) 119/53 36/20 0.50
 Disease duration (years) 5.0 ± 4.9 5.7 ± 4.7 0.30
 LED (mg) 522.9 ± 440.0 663.5 ± 545.5 0.09
NMSS total 41.6 ± 33.0 73.4 ± 48.8 < 0.001
 1. Dizziness 1.2 ± 2.2 1.9 ± 2.8 0.08
 2. Falls 0.3 ± 1.2 0.8 ± 2.1 0.019
 3. Somnolence 2.0 ± 3.0 2.8 ± 3.9 0.15
 4. Fatigue 2.6 ± 3.1 4.4 ± 4.4 0.009
 5. Sleep initiation 2.7 ± 3.7 4.3 ± 4.5 0.020
 6. Restless legs 1.5 ± 2.7 3.0 ± 3.8 0.001
 7. Loss of interest 1.1 ± 2.5 2.0 ± 3.5 0.10
 8. Motivation 1.2 ± 2.5 2.3 ± 3.7 0.19
 9. Feeling nervous 1.1 ± 2.7 2.9 ± 3.8 0.005
 10. Depression 1.7 ± 2.8 3.2 ± 3.8 0.002
 11. Flat moods 1.3 ± 2.3 1.6 ± 2.8 0.64
 12. Anhedonism 1.1 ± 2.4 1.6 ± 3.3 0.64
 13. Hallucinations 0.5 ± 1.4 0.8 ± 2.2 0.42
 14. Delusions 0.2 ± 1.0 0.4 ± 1.6 0.80
 15. Diplopia 0.3 ± 1.1 0.9 ± 2.6 0.25
 16. Concentration 1.3 ± 2.3 2.1 ± 2.9 0.049
 17. Recall 1.5 ± 2.5 2.6 ± 3.0 0.006
 18. Forgetfulness 1.3 ± 2.3 1.8 ± 2.5 0.17
 19. Sialorrhoea 1.2 ± 2.3 2.2 ± 3.3 0.018
 20. Dysphagia 0.7 ± 1.8 1.4 ± 2.5 0.013
 21. Constipation 1.6 ± 2.5 3.1 ± 4.2 0.047
 22. Urgency 2.4 ± 3.5 4.7 ± 4.6 0.001
 23. Frequency 1.6 ± 3.0 2.9 ± 3.9 0.036
 24. Nocturia 2.7 ± 3.6 3.2 ± 4.2 0.72
 25. Libido 1.4 ± 2.9 1.9 ± 3.3 0.10
 26. Performing sex 1.3 ± 3.0 1.3 ± 2.9 0.68
 27. Pain 1.4 ± 2.7 3.7 ± 4.2 < 0.001
 28. Anosmia 2.7 ± 3.7 4.1 ± 4.7 0.046
 29. Weight change 0.7 ± 2.0 1.4 ± 3.2 0.28
 30. Hyperhidrosis – – –
PDSS 109.7 ± 27.2 98.1 ± 28.2 0.006
ESS 7.4 ± 4.7 9.0 ± 6.0 0.16
HADS anxiety 5.3 ± 3.8 8.1 ± 4.3 < 0.001
HADS depression 4.9 ± 3.9 7.0 ± 4.1 < 0.001
PDQ-8 7.1 ± 5.4 11.7 ± 7.4 < 0.001
SCOPA-motor 10.3 ± 5.0 11.4 ± 5.2 0.13
SCOPA-daily living 5.1 ± 3.3 6.8 ± 4.4 0.019
SCOPA-complications 1.5 ± 1.9 3.0 ± 3.3 0.002
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Moreover, PD patients exhibiting hyperhidrosis have 
higher dyskinesia scores, worse quality of life, more severe 
sleep disorders, and higher anxiety and depression levels. 
The autonomic phenotype of this subset was characterised 
by NMS such as sleep, depression, anxiety, urinary prob-
lems and pain. Based on these results, the presence and 
severity of hyperhidrosis could be used as simple clini-
cal screening tool to support the presence of this specific 
subtype in PD.
The above statement is underpinned by the fact that 
hyperhidrosis in our cohort closely resembles the auto-
nomic phenotype that has been previously proposed in PD 
[6]. Clinically, it has been proposed that this PD subtype pre-
sents with dysautonomia, such as sexual dysfunction, con-
stipation, urinary frequency and urgency. Other symptoms 
included in this phenotype are postural and post-prandial 
hypotension, and sialorrhoea [16]. Also fatigue, which was 
significantly more severe in our cohort among patients suf-
fering from hyperhidrosis, has been implicated in this sub-
type of PD [6].
Identifying distinct subtypes in PD is of great importance 
for therapeutic and prognostic reasons and forms the basis 
of the emerging concept of holistic personalised medicine 
strategies for PD. It has been shown that PD patients with 
autonomic dysfunction in general, but also individual auto-
nomic abnormalities, such as sweating disorders, show a 
more rapid disease progression and shorter survival com-
pared to those without such abnormalities [17]. Moreover, 
hyperhidrosis is associated with pain and decreased quality 
of life [16]. Whether treatment of autonomic symptoms and 
hyperhidrosis leads to slowing down of the disease progres-
sion and improvement of survival remains currently unclear. 
Moreover, due to the lack of validated and evidence-based 
algorithms, the treatment of hyperhidrosis in PD patients 
remains challenging, and its effectiveness limited.
The only motor difference between PD patients suffering 
from hyperhidrosis and those without was an increased sever-
ity of dyskinesia. It might be argued that, from a mechanistic 
point of view, dyskinesia itself leads to increased sweating. 
However, a recent meta-analysis on the risk of excessive sweat-
ing with antidepressants showed that hyperhidrosis is associ-
ated with increased dopamine receptor affinity of specific anti-
depressants [18], underlining the link between hyperhidrosis 
and dopamine metabolism. Other explanations could be found 
in the hypothalamus, one of the key structures in thermoregu-
lation. It is known that the hypothalamus is affected by Lewy 
Fig. 1  Non-motor symptom Scale total scores differences between 
Parkinson’s disease patients with hyperhidrosis and no hyperhidro-
sis and across the different severities of hyperhidrosis. NMSQ Non-
motor symptom questionnaire, NMSS Non-motor symptom scale, 
***p < 0.001. Statistical differences tested using Mann–Whitney U 
and Kruskal–Wallis tests
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Table 2  Demographics and 
(non-)motor profiles (non-
motor symptom scale based) 
associated with hyperhidrosis in 
Parkinson’s disease
Statistical differences tested using Kruskal–Wallis test
M male, F female, LED Levodopa equivalent dose, NMSS non-motor symptom scale, PDSS Parkinson’s 
disease sleep scale, ESS Epworth sleepiness scale, HADS hospital anxiety and depression scale, PDQ-8 
8-item Parkinson’s disease quality of life scale, SCOPA Scales for Outcomes in Parkinson’s disease
Analysis 2 (NMSS item 30)
Hyperhidrosis No (n = 267) Mild (n = 49) Moderate (n = 17) Severe (n = 19) P
Demographics
 Age (years) 64.5 ± 11.6 63.4 ± 11.4 60.8 ± 11.4 62.3 ± 11.5 0.61
 Gender (M/F) 183/84 33/16 12/5 8/11 0.13
 Disease duration (years) 5.2 ± 5.1 6.3 ± 5.6 4.2 ± 3.2 6.9 ± 3.8 0.033
 LED (mg) 522.7 ± 467.2 613.4 ± 477.6 631.5 ± 473.8 815.3 ± 460.0 0.017
NMSS total 41.9 ± 32.3 58.2 ± 39.6 77.8 ± 41.6 93.7 ± 52.6 < 0.001
 1. Dizziness 1.4 ± 2.2 1.5 ± 2.5 1.9 ± 3.2 2.7 ± 3.3 0.31
 2. Falls 0.4 ± 1.3 0.4 ± 1.2 0.4 ± 1.2 1.4 ± 3.0 0.028
 3. Somnolence 1.7 ± 3.0 2.4 ± 3.1 2.1 ± 3.3 3.9 ± 4.2 0.014
 4. Fatigue 2.4 ± 3.1 4.2 ± 3.9 5.0 ± 3.7 6.1 ± 4.6 < 0.001
 5. Sleep initiation 2.7 ± 3.6 3.5 ± 3.6 4.9 ± 4.2 6.9 ± 4.1 < 0.001
 6. Restless legs 1.6 ± 2.8 1.8 ± 2.0 4.2 ± 3.9 3.7 ± 3.8 < 0.001
 7. Loss of interest 1.1 ± 2.4 1.3 ± 2.6 3.4 ± 4.1 1.1 ± 3.0 0.31
 8. Motivation 1.1 ± 2.4 1.8 ± 2.8 2.2 ± 4.1 2.1 ± 3.5 0.15
 9. Feeling nervous 1.7 ± 2.9 2.3 ± 3.1 2.5 ± 3.6 3.7 ± 4.5 0.31
 10. Depression 1.7 ± 2.8 2.7 ± 3.3 3.5 ± 3.3 2.5 ± 3.9 0.005
 11. Flat moods 1.2 ± 2.2 1.7 ± 2.7 1.9 ± 2.7 1.7 ± 3.2 0.37
 12. Anhedonism 0.9 ± 2.2 1.9 ± 3.3 1.4 ± 3.0 1.0 ± 2.8 0.008
 13. Hallucinations 0.5 ± 1.5 0.5 ± 1.3 0.6 ± 1.37 1.6 ± 3.9 0.78
 14. Delusions 0.2 ± 0.8 0.5 ± 1.7 0.6 ± 1.7 0.9 ± 3.0 0.86
 15. Diplopia 0.4 ± 1.4 0.5 ± 1.9 1.3 ± 3.4 0.3 ± 1.4 0.66
 16. Concentration 1.5 ± 2.4 1.7 ± 2.6 1.8 ± 2.1 2.8 ± 4.1 0.83
 17. Recall 1.6 ± 2.4 2.1 ± 2.7 2.1 ± 2.0 3.2 ± 3.8 0.09
 18. Forgetfulness 1.4 ± 2.4 1.7 ± 2.6 1.7 ± 2.4 2.1 ± 2.9 0.53
 19. Sialorrhoea 1.1 ± 2.4 1.6 ± 2.8 0.8 ± 2.0 3.2 ± 4.0 0.049
 20. Dysphagia 0.7 ± 1.8 1.4 ± 2.8 1.5 ± 2.2 0.6 ± 1.1 0.11
 21. Constipation 1.9 ± 2.9 2.1 ± 3.2 1.9 ± 3.2 3.9 ± 4.5 0.05
 22. Urgency 2.4 ± 3.5 3.4 ± 4.2 4.3 ± 4.9 4.8 ± 4.6 0.029
 23. Frequency 1.7 ± 2.9 2.2 ± 3.6 1.9 ± 4.0 4.6 ± 4.2 0.003
 24. Nocturia 2.6 ± 3.4 2.6 ± 3.6 3.5 ± 4.2 4.1 ± 7.7 0.28
 25. Libido 1.3 ± 2.7 1.3 ± 2.8 3.4 ± 4.4 2.0 ± 3.3 0.68
 26. Performing sex 1.2 ± 2.8 1.3 ± 2.9 2.3 ± 4.4 1.7 ± 3.6 0.21
 27. Pain 2.0 ± 3.2 2.8 ± 3.6 4.7 ± 4.7 3.5 ± 4.6 0.004
 28. Anosmia 2.8 ± 3.8 3.4 ± 4.1 5.4 ± 4.4 5.33 ± 4.7 0.004
 29. Weight change 0.7 ± 2.0 1.0 ± 2.0 1.4 ± 4.0 2.3 ± 4.2 0.08
 30. Hyperhidrosis – – – – –
PDSS 109.2 ± 26.6 95.1 ± 31.1 95.9 ± 22.3 89.4 ± 23.0 < 0.001
ESS 7.4 ± 4.8 8.5 ± 5.9 8.9 ± 6.0 9.6 ± 5.8 0.44
HADS anxiety 5.8 ± 3.9 7.6 ± 3.8 7.6 ± 4.3 8.4 ± 5.1 0.003
HADS depression 5.3 ± 3.7 6.3 ± 3.7 7.5 ± 5.0 6.5 ± 3.3 0.043
PDQ-8 7.7 ± 5.9 11.1 ± 6.6 10.5 ± 6.3 9.6 ± 5.8 < 0.001
SCOPA-motor 10.4 ± 5.4 11.5 ± 6.5 12.1 ± 4.4 13.9 ± 6.5 0.047
SCOPA-daily living 5.5 ± 3.7 6.1 ± 4.0 6.5 ± 4.1 8.1 ± 4.8 0.08
SCOPA-complications 1.7 ± 2.2 2.8 ± 3.1 2.1 ± 1.7 4.4 ± 3.6 0.001
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pathology in PD [19] and also the hypothalamic functional 
connectivity is disturbed in autonomic dysfunction in PD [20]. 
Furthermore, hyperhidrosis in PD is often episodic [18] and 
similar sweat attacks occur during menopause, where they 
have been related to brain noradrenergic over activity [21]. 
Perhaps, similar changes to the noradrenergic system occur in 
PD, explaining hyperhidrosis.
Limitations in this study include the cross-sectional design 
and retrospective data mining, rather than a longitudinal fol-
low-up to assess the development of specific symptoms in PD 
patients suffering from hyperhidrosis. In addition, we did not 
assess symptoms related to impaired thermoregulation, and 
dehydration, often related to prominent dyskinesias [22]. Also, 
the presence and severity of hyperhidrosis were only assessed 
through history taking and not objectively assessed. Moreover, 
both NMSS and NMSQ contain only one item each addressing 
hyperhidrosis [14, 15]. The NMSS and NMSQ are, however, 
validated tools for assessing NMS in PD patients and are com-
monly used tools in outpatient clinics, reflecting a real-world 
experience. As such we feel that our current results are useful, 
also considering that there were no group differences regarding 
disease duration, Hoehn and Yahr stages, LED and sex which 
in themselves can also influence NMS burden and dyskinesia 
severity.
In summary, the presence and severity of hyperhidrosis in 
PD patients coincides with an apparent PD endophenotype 
with dysautonomia which is associated with sleep disorders 
and a higher rate of dyskinesia. We suggest that asking about 
hyperhidrosis can be used as a simple screening tool to identify 
this specific subset of PD patients with dominant autonomic 
features, although further research is needed.
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